Recent Press Releases

Captisol-Enabled™ (Propylene Glycol-Free) Melphalan Meets Primary Endpoint

CE Melphalan is being developed as a novel version of the well-established conditioning treatment in autologous transplant for patients with multiple myeloma. CE Melphalan does not contain propylene...

Novel stapled peptide nanoparticle combination prevents RSV infection, study finds

17-Apr-2014 Contact: Anne DeLotto Baier abaier@health.usf.edu 813-974-3300 University of South Florida (USF Health) A Dana-Farber/Boston Children's and VA Hospital/University of South Florida...

Mylan Launches First Generic ORTHO EVRA® Patch

PITTSBURGH, April 16, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched XULANE™ (Norelgestromin / Ethinyl...

Novel Hydrogel Sealant and Sustained Release Drug Technology Data to be Presented at the ASCRS Annual Symposium

April 21, 2014 08:00 AM Eastern Daylight Time ASCRS-ASOA Symposium & Congress 2014 BEDFORD, Mass--(BUSINESS WIRE)--Ocular Therapeutix, Inc., developers of ophthalmic therapeutic products using a...

New Anti-fibrosis Drug with Molecular Targeting DDS Completed Phase-1a Dose Escalation

Nitto Denko Corporation (Nitto) has been developing a new RNAi based drug for treating fibrosis in liver and other organs since 2008 in collaboration with Prof.Yoshiro Niitsu of Sapporo Medical...

Moberg Pharma Acquires Global Rights to Novel Topical Formulation for Treatment of Oral Pain

April 14, 2014 02:42 AM Eastern Daylight Time STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Moberg Pharma AB (OMX: MOB) (STO:MOB) announced that the company has entered into a definitive agreement...

Results from Non-Tuberculous Mycobacteria (NTM) Study Using Aradigm's Liposomal Ciprofloxacin to be Presented at the American Thoracic Society 2014 International Conference

April 15, 2014 07:00 AM Eastern Daylight Time HAYWARD, Calif.--(BUSINESS WIRE)--Scientists from the Oregon State University, Corvallis (OSU) and Aradigm Corporation (OTCBB: ARDM) (the...

UPDATE -- Alliqua Raises $20.3 Million in Private Placement of Equity and Exercise of Warrants

LANGHORNE, Pa., Apr 15, 2014 (GLOBE NEWSWIRE via COMTEX) -- In a release issued earlier today under the same headline by Alliqua, Inc. ALQA -2.65% , please note that details of the common stock...

Celsion's ThermoDox Plus High Intensity Focused Ultrasound Highlighted at 14th International Symposium on Therapeutic Ultrasound

Data Supports Development as Non-Invasive Treatment Regimen in a Variety of Cancer Indications LAWRENCEVILLE, N.J., April 9, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) announced today...

Novaliq GmbH Announces Launch of a Phase 1 Study Following US and European Patent Approval of CyclASol® (Cyclosporin) Eye Drops

April 03, 2014 09:00 AM Eastern Daylight Time HEIDELBERG, Germany--(BUSINESS WIRE)--Novaliq GmbH today announced the commencement of a Phase 1 study for CyclASol (Cyclosporin solution) following US...

Starpharma expands its Drug Delivery Program with AstraZeneca

7 April 2014 Melbourne, Australia; Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced the signing of a second, expanded agreement with AstraZeneca in the field of cancer medicine using...

BioLight Announces IND Filing with FDA for Phase I/IIa Clinical Study of its Controlled Release Latanoprost Insert for the Treatment of Glaucoma

TEL-AVIV, Israel, March 31, 2014 /PRNewswire/ -- BioLight Israeli Life Sciences Investments Ltd. (TASE: BOLT; OTCQX: BLGTY), a firm that invests in, manages and commercializes biomedical innovations...

Particle Sciences and Actavis Enter into Joint Development Agreement

BETHLEHEM, Pa., April 1, 2014 /PRNewswire/ -- Particle Sciences, a drug delivery Contract Development and Manufacturing Organization (CDMO), today announced that they have entered into an exclusive...

Ablative Solutions Receives FDA Clearance for the Peregrine System™ Infusion Catheter

KALAMAZOO, Mich., April 2, 2014 /PRNewswire/ -- Ablative Solutions, Inc., a privately-held clinical stage company, announced today that it has received 510(k) clearance from the U.S. Food and Drug...

Alnylam Receives Positive Opinion for Orphan Drug Designation in the European Union for ALN-TTRsc, a Subcutaneously Delivered RNAi Therapeutic for the Treatment of Transthyretin-Mediated Amyloidosis (ATTR)

April 02, 2014 08:00 AM Eastern Daylight Time CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, announced today that the European...

Good Vibrations: Using Light-Heated Water to Deliver Drugs

Good Vibrations: Using Light-Heated Water to Deliver Drugs Researchers use near-infrared light to warm water-infused polymeric particles Date: April 01, 2014 Researchers from the...

OptiNose Announces FDA Acceptance of New Drug Application for AVP-825 for the Acute Treatment of Migraine

OptiNose Announces FDA Acceptance of New Drug Application for AVP-825 for the Acute Treatment of Migraine AVP-825 relies on novel closed palate Breath Powered™ drug delivery technology ...

Oramed Pharmaceuticals Announces First Patient Enrolled in a US Phase 2a Trial for ORMD-0801 in Treatment of Type 1 Diabetes

Oramed Pharmaceuticals Announces First Patient Enrolled in a US Phase 2a Trial for ORMD-0801 in Treatment of Type 1 Diabetes JERUSALEM, March 27, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc....

FDA Approves Optiguide® DCYL700 Fiber Optic Diffuser Series Flexible Fiber

Supplemental approval will expand PDT with Photofrin® treatments in specific lung and esophageal cancers TORONTO AND BANNOCKBURN, IL, March 26, 2014 /PRNewswire/ - Concordia Healthcare Corp....

Avanir Pharmaceuticals Announces Acceptance of New Drug Application for AVP-825 for the Acute Treatment of Migraine

ALISO VIEJO, Calif., March 26, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's New...